What are regulatory T cells (Treg) regulating in cancer and why?

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 327-334

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; FOXP3; Inducible (i) Treg; Inflammation; Prognosis; Regulatory T cells (Treg)

Indexed keywords

ADENOSINE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL INTERACTION; CHRONIC INFLAMMATION; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; EFFECTOR CELL; ENVIRONMENTAL FACTOR; HUMAN; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR PROMOTION;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84862135169     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.03.004     Document Type: Review

References (120)

1. Eggremont A.M. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009, 15:6745-6747.
2. Alpizar Y.A., Chain B., Collins M.K., Greenwood J., Katz D., Stauss H.J., et al. Ten years of progress in vaccination against cancer the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 2011, 60:1127-1135.
3. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
4. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008, 27:5869-5885.
5. Frey A.B., Monu N. Signaling defects in anti-tumor T cells. Immunol Rev 2008, 222:192-195.
6. Hoskin D.W., Mader J.S., Furlong S.J., Conrad D.M., Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008, 32:527-535.
7. Blay J., White T.D., Hoskin D.W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997, 57:2602-2605.
8. Sitarz R., Leguit R.J., de Leng W.W., Morsink F.H., Polkowski W.P., Maciejewski R., et al. Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cell Oncol 2009, 31:475-485.
9. Wang D., Dubois R.N. Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193.
10. Zhang Y., Liu Q., Zhang M., Yu Y., Liu X., Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009, 182:3801-3808.
11. Chen W.J., Konkel J.E. TGF-β and adaptive FOXP3+ regulatory T cells. J Mol Cell Biol 2010, 2:30-36.
12. Sa G., Das T., Moon C., Hilston C.M., Rayman P.A., Rini B.I., et al. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009, 69:3095-3104.
13. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
14. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003, 171:6891-6899.
15. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006, 66:5527-5536.
16. Whiteside T.L. Immune responses to malignancies. J Allergy Clin Immunol 2010, 125:S272-S283.
17. Whiteside T.L. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006, 130:103-124.
18. Poschke I., Mougiakakos D., Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011, 60:1161-1171.
19. Reichert T.E., Strauss L., Wagner E.M., Gooding W., Whiteside T.L. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002, 8:3137-3145.
20. Ferrone S., Whiteside T.L. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007, 16:755-774.
21. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
22. Uppaluri R., Dunn G.P., Lewis J.S. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immunol 2008, 8:16.
23. Imai N., Ikeda H., Tawara I., Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol 2009, 39:241-253.
24. Oble D.A., Loewe R., Yu P., Mihm M.C. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immunol 2009, 9:3.
25. 1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007, 13:4345-4354.
26. highFOXP3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6301-6311.
27. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
28. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv Cancer Res 2010, 107:57-117.
29. Bergmann C., Strauss L., Wang Y., Szczepanski M.J., Lang S., Johnson J.T., et al. T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008, 14:3706-3715.
30. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
31. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
32. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24:5373-5380.
33. Perrone G., Ruffini P.A., Catalano V., Spino C., Santini D., Muretto P., et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008, 44:1875-1882.
34. Bohling S.D., Allison K.H. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008, 21:1527-1532.
35. Czystowska M., Strauss L., Bergmann C., Szajnik M., Rabinowich H., Whiteside T.L. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 2010, 88:577-588.
36. highFoxp3+ Treg kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009, 182:1469-1480.
37. Shevach E.M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
38. Sitkovsky M.V., Kjaergaard J., Lukashev D., Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008, 14:5947-5952.
39. Raimondi G., Turner M.S., Thomson A.W., Morel P.A. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007, 27:61-95.
40. Jonuleit H., Schmitt E., Stassen M., Tuehenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
41. Roncarolo M.G., Bacchetta R., Bordignon C., Narula S., Levings M.K. Type 1 T regulatory cells. Immunol Rev 2001, 182:68-79.
42. Bergmann C., Strauss L., Zeidler R., Lang S., Whiteside T.L. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007, 67:8865-8873.
43. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10 secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
44. Hori S., Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004, 6:745-751.
45. Haxhinasto S., Mathis D., Benoist C. The Akt-mTOR axis regulates denovo differentiation of CD4+FOXP3+ cells. J Exp Med 2008, 205:565-574.
46. Roncarolo M.G., Gregori S., Roncarolo M.G., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol 2008, 38(4):925-927.
47. Strauss L., Bergmann C., Whiteside T.L. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007, 121:2473-2483.
48. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008, 224:166-182.
49. Franceschini D., Paroli M., Francavilla V., Videtta M., Marrone S., Labbadia G., et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009, 119:551-564.
50. + T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008, 180:2967-2980.
51. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69:2000-2009.
52. Kleinewietfeld M., Puentes F., Borsellino G., Battistini L., Rotzschke O., Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005, 105:2877-2886.
53. Menning A., Hopken U.E., Siegmund K., Lipp M., Hamann A., Huehn J. Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. Eur J Immunol 2007, 37:1575-1583.
54. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
55. Ermann J., Fathman C.G. Costimulatory signals controlling regulatory T cells. Proc Natl Acad Sci U S A 2003, 100:15292-15293.
56. Elkord E., Sharma S., Burt D.J., Hawkins R.E. Expanded subpopulation of Foxp3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol 2011, 140:218-222.
57. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
58. Kleinewietfeld M., Starke M., Di Mitri D., Borsellino G., Battistini L., Rotzschke O., et al. CD49d provides access to untouched human Foxp3+ Treg free of contaminating effector cells. Blood 2009, 113:827-836.
59. Peters J.H., Preijers F.W., Woestenenk R., Hilbrands L.B., Koenen H.J., Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One 2008, 3:e3161.
60. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-1265.
61. Borsellino G., Kleinewietfeld M., DiMitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
62. Mandapathil M., Lang S., Gorelik E., Whiteside T.L. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009, 346:55-63.
63. Bynoe M.S., Viret C. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol 2008, 29:99-102.
64. Dwyer K.M., Hanidziar D., Putheti P., Hill P.A., Pommey S., McRae J.L., et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010, 10:2410-2420.
65. Clayton A., Al-Taei S., Webber J., Mason M.D., Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011, 187:676-683.
66. 2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010, 285:27571-27580.
67. + regulatory T cells (Treg). J Biol Chem 2010, 285:7176-7186.
68. Dwyer K.M., Deaglio S., Gao W., Friedman D., Strom T.B., Robson S.C. CD39 and control of cellular immune responses. Purinergic Signal 2007, 3:171-180.
69. Schuler P.J., Harasymczuk M., Schilling B., Lang S., Whiteside T.L. Separation of human CD4(+)CD39(+) T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011, 369:59-68.
70. Moncrieffe H., Nistala K., Kamhieh Y., Evans J., Eddaoudi A., Eaton S., et al. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 2010, 185:134-143.
71. Zarek P.E., Powell J.P. Adenosine and anergy. Autoimmunity 2007, 40:425-432.
72. Schenk U., Frascoli M., Proietti M., Geffers R., Traggiai E., Buer J., et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011, 4:ra12.
73. Schmidt A., Oberle N., Weis E.M., Vobis D., Frischbutter S., Baumgrass R., et al. Human regulatory T cells rapidly suppress T cell-receptor-induced Ca2+, NF-κB, and NFAT signaling in conventional T cells. Sci Signal 2011, 4:ra 90.
74. Sojka D.K., Huang Y.H., Fowell D.J. Mechanisms of regulatory T-cell suppression-a diverse arsenal for a moving target. Immunology 2008, 124:13-22.
75. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of Foxp3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
76. Karanikas V., Speletas M., Zamanakou M., Kalala F., Loules G., Kerenidi T., et al. Foxp3 expression in human cancer cells. J Transl Med 2008, 6:19.
77. Bindea G., Mlecnik B., Fridman W.H., Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011, 33:335-340.
78. Toker A., Huehn J. To be or not to be a Treg cell: lineage decisions controlled by epigenetic mechanisms. Sci Signal 2011, 4:pe4.
79. Schulze Zur Wiesch J., Thomssen A., Hartjen P., Toth I., Lehmann C., Meyer-Olson D., et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FOXP3+ Tregulatory cells correlates with progressive disease. J Virol 2011, 85:1287-1297.
80. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
81. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010, 21:3-10.
82. Ma Y., Kepp O., Ghiringhelli F., Apetoh L., Aymeric L., Locher C., et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010, 22:113-124.
83. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192.
84. Frey D.M., Droeser R.A., Viehl C.T., Zlobec I., Lugli A., Zingg U., et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatched repair-proficient colorectal cancer patients. Int J Cancer 2010, 126:2635-2643.
85. Badoual C., Hans S., Rodriquez J., Peyrard S., Klein C., Agueznay Nel H., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472.
86. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011, 60:909-918.
87. Kryczek I., Liu R., Wang G., Wu K., Shu X., Szeliga W., et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009, 69:3995-4000.
88. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15:79-80.
89. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15:1016-1022.
90. Erdman S.E., Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010, 127:768-779.
91. Lan Q., Fan H., Quesniaux V., Ryffel B., Liu Z., Zhen S.G. Induced FOXP3+ regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases. J Mol Cell Biol 2012, 4:22-28.
92. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955.
93. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71:5601-5605.
94. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
95. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
96. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
97. Xia D., Wang D., Kim S.H., Katoh H., Dubois R.N. Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat Med 2012, 18:224-226.
98. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
99. Mills K.H.G. Induction, function and regulation of IL-17 producing T cells. Eur J Immunol 2008, 38:2636-2649.
100. Tosolini M., Kirilovsky A., Miecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
101. Whiteside T.L. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005, 24:95-105.
102. Hooper S.J., Wilson M.J., Crean S.J. Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck 2009, 31:1228-1239.
103. Kesselring R., Thiel A., Pries R., Trenkle T., Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010, 103:1245-1254.
104. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Lenzner D.E., Jackson E.K., et al. Increased ectonucleotidase expression and activity in Treg of patients with head and neck cancer. Clin Cancer Res 2009, 15:6348-6357.
105. Zhang Y.L., Li J., Mo H.Y., Qiu F., Zheng L.M., Qian C.N., et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010, 9:4.
106. Perez S.A., Karamouzis M.V., Skarlos D.V., Ardavanis A., Sotiriadou N.N., Iliopoulou E.G., et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 2007, 13:2714-2721.
107. Audia S., Nicolas A., Cathelin D., Larmonier N., Ferrand C., Foucher P., et al. Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clin Exp Immunol 2007, 150:523-530.
108. Rech A.J., Mick R., Kaplan D.E., Chang K.M., Domchek S.M., Vanderheide R.H. Homeostasis of peripheral FOXP3+CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010, 59:599-607.
109. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H., Ellis I.O., et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011, 127:99-108.
110. Jacobs J.F., Nierkens S., Figdor C.G., de Vries I.J., Adema G.J. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol 2012, 13:e32-e42.
111. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005, 201:1591-1602.
112. Audia S.A., Nicholas D., Cathelin N., Larmonier C., Ferrand P., Foucher P., et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007, 150:523-530.
113. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648.
114. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:99-106.
115. Hobeika A.C., Morse M.A., Osada T., Peplinski S., Lyerly H.K., Clay T.M. Depletion of human regulatory T cells. Methods Mol Biol 2011, 707:219-231.
116. Finke J.H., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
117. de Vries I.J., Castelli C., Huygens C., Jacobs J.F., Stockis J., Schuler-Thurner B., et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2011, 17:841-848.
118. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
119. Correale P., Rotundo M.S., Del Vecchio M.T., Remondo C., Migali C., Ginanneschi C., et al. Regulatory (FOXP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother 2010, 33:435-441.
120. Whiteside T.L. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012, 61:283-288.